- Home
- UBSI vs MDGL Comparison
UBSI vs MDGL Comparison
Compare UBSI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- MDGL
- Stock Information
- Founded
- UBSI 1982
- MDGL 2011
- Country
- UBSI United States
- MDGL United States
- Employees
- UBSI N/A
- MDGL N/A
- Industry
- UBSI Major Banks
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- UBSI Finance
- MDGL Health Care
- Exchange
- UBSI Nasdaq
- MDGL Nasdaq
- Market Cap
- UBSI 5.4B
- MDGL 6.1B
- IPO Year
- UBSI N/A
- MDGL N/A
- Fundamental
- Price
- UBSI $37.10
- MDGL $437.23
- Analyst Decision
- UBSI Hold
- MDGL Strong Buy
- Analyst Count
- UBSI 3
- MDGL 10
- Target Price
- UBSI $40.50
- MDGL $485.78
- AVG Volume (30 Days)
- UBSI 637.6K
- MDGL 292.1K
- Earning Date
- UBSI 10-23-2025
- MDGL 10-30-2025
- Dividend Yield
- UBSI 3.96%
- MDGL N/A
- EPS Growth
- UBSI 7.20
- MDGL N/A
- EPS
- UBSI 2.84
- MDGL N/A
- Revenue
- UBSI $1,071,104,000.00
- MDGL $515,547,000.00
- Revenue This Year
- UBSI $22.52
- MDGL $394.08
- Revenue Next Year
- UBSI $4.28
- MDGL $61.80
- P/E Ratio
- UBSI $13.14
- MDGL N/A
- Revenue Growth
- UBSI 5.86
- MDGL 3421.98
- 52 Week Low
- UBSI $30.51
- MDGL $200.63
- 52 Week High
- UBSI $44.43
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- UBSI 47.88
- MDGL 56.77
- Support Level
- UBSI $36.49
- MDGL $417.70
- Resistance Level
- UBSI $38.07
- MDGL $463.63
- Average True Range (ATR)
- UBSI 0.63
- MDGL 15.31
- MACD
- UBSI -0.04
- MDGL -3.01
- Stochastic Oscillator
- UBSI 39.87
- MDGL 42.53
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.